A Study To EvaluateThe Efficacy Of Tigecycline Plus Piperacillin Sodium and Tazobactam Sodium In Febrile Neutropenia Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006543

Enrollment

Unknown

Registered

2015-06-09

Start date

2015-06-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Febrile Neutropenia

Interventions

treatment group :Tigecycline Plus Piperacillin Sodium

control group:Tazobactam Sodium

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. patients with malignant hematologic disease aged >=18 years old; 2. patients with febrile neutropenia; 3. patients with pulmonary infection,complicated skin infections,complicated abdominal infections or blood infection; 4. able and willing to provide signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergy; 2. Pregnancy.

Design outcomes

Primary

Measure	Time frame
Fever duration;success rate of clinical treatment;	—

Secondary

Measure	Time frame
rate of bacterial clearance;length of hospitalization;safety;	—

Countries

China

Contacts

Public ContactAining Sun

sunaining@suda.edu.cn+86 0512 67781856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026